FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered: use of the tri-substituted glycerol compounds of formula (I) 
in preparing a therapeutic agent with said therapeutic agent applied with at least one other therapeutic agent containing one or more additional active ingredients specified in a group consisting of antimetabolites, herbal alkaloids, topoisomerase II inhibitors, proteasome inhibitors; related combination and an in vitro method for determining sensitivity of hematological malignant tumours to a combination of the therapeutic agents as specified in the present invention.
EFFECT: what is presented is a synergic cytotoxic effect of the compound of formula (I) of edelfosine in a combination with the proteasome inhibitor Bortezomib, with the antimetabolite fludarabine, cytarabine, the topoisomerase II inhibitor edelfosine.
11 cl, 10 dwg, 4 tbl
